（文章来源：证券日报） 证券日报网讯 2月2日，华兰疫苗在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东人 数为两万两千余户。 ...

Core Viewpoint - The company, Hualan Vaccine, is positioned as a leading player in the domestic influenza vaccine market, with a significant number of batches approved for distribution in 2025 [2] Group 1: Company Performance - Hualan Vaccine reported that it ranked among the top in China for the number of influenza vaccine batch approvals, with a total of 57 batches issued in the 2025 fiscal year according to public data from the China National Institute for Food and Drug Control [2] - The company is actively distributing influenza vaccines nationwide based on orders from local disease control centers, indicating a responsive supply chain to market demand [2] Group 2: Market Context - The predominant strain of influenza virus currently circulating in the domestic market is the H3N2 subtype, and the company's vaccine is effective in providing prevention against this strain [2]

Core Viewpoint - The company, Hualan Vaccine, emphasizes its strong collaboration with its controlling shareholder, Hualan Biological, in various aspects such as biopharmaceutical research and development, production quality system construction, supply chain management, and compliance experience [1] Group 1 - The company and Hualan Biological are committed to building and managing the "Hualan" brand, which has been recognized as a well-known trademark in China, indicating good market recognition and brand reputation [1] - Some vaccine products from the company have complementary clinical applications with related immunological products from Hualan Biological, such as rabies vaccine and tetanus vaccine, which can be used in conjunction with corresponding human immunoglobulin to achieve synergistic effects of active and passive immunity [1]

Core Viewpoint - The company, Hualan Vaccine, emphasizes its collaborative development with its controlling shareholder, Hualan Biological, focusing on shared resources and complementary product offerings in the vaccine sector [1] Group 1: Collaboration and Synergy - The company and Hualan Biological have established a solid foundation for collaboration in areas such as bioproduct research and development management, production quality system construction, supply chain management, and compliance experience [1] - Both entities are committed to the construction and management of the "Hualan" brand, which has been recognized as a famous trademark in China, indicating strong market recognition and brand reputation [1] Group 2: Product Complementarity - Certain vaccine products from the company have complementary applications with Hualan Biological's related immunological products, such as rabies vaccine and tetanus vaccine, which can be used in conjunction with corresponding human immunoglobulin to enhance both active and passive immunity [1]

Investment Rating - The report maintains a strong rating for the pharmaceutical sector, indicating it is expected to outperform the market [6]. Core Insights - The targeted PAM pathway represents a potential market of approximately $10 billion, with significant implications for breast and prostate cancer treatments [4][16]. - Celcuity's Gedatolisib is highlighted as a promising PAM inhibitor, showing comparable efficacy to existing therapies and is under FDA priority review with a PDUFA date set for July 17, 2026 [4][37]. - The report emphasizes the importance of innovation and international expansion in the pharmaceutical industry, suggesting that companies focusing on these areas will likely thrive [4]. Summary by Sections Targeted PAM Pathway - The PAM pathway is identified as one of the most underdeveloped targets in solid tumors, with mutations occurring in 38% of cancer patients [4][16]. - Gedatolisib is noted for its effectiveness across various PI3K subtypes and its potential to establish new treatment standards in HR+/HER2- advanced breast cancer [25][37]. - HMPL-A251, developed by Hutchison China MediTech, is a HER2-targeted PAM inhibitor that has shown strong anti-tumor activity in both HER2-positive and low-expressing tumors [41][50]. Market Review and Trends - The report reviews the performance of the pharmaceutical sector from January 26 to January 30, 2026, noting a decline of 3.3% in the CITIC Pharmaceutical Index, which underperformed the CSI 300 Index by 3.4 percentage points [3][60]. - The report highlights the best-performing stocks during this period, including Cap Bio (+26.5%) and Hualan Biological (+12.8%) [3][74]. - The overall valuation of the pharmaceutical sector as of January 30, 2026, is reported at 29.09, reflecting a slight decrease of 0.87% [69].

证券日报网讯1月30日，华兰疫苗（301207）在互动平台回答投资者提问时表示，上市公司股价受经济 环境、公司业绩、二级市场走势等多因素影响，公司将努力维护投资者权益。 ...

2026 年 01 月 29 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260129）：Immix 在研 NXC-201 获 FDA 突破 性疗法认定 ◼ 走势比较 (10%) 0% 10% 20% 30% 40% 25/2/5 25/4/17 25/6/27 25/9/6 25/11/16 26/1/26 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260128）：罗氏 减重疗法 CT-388 二期临床成功>>-- 2026-01-28 <<太平洋医药日报（20260127）： Sarepta 基因疗法 Elevidys 三期临 床成功>>--2026-01-28 <<太平洋医药日报（20260126）：英矽 智能 ISM8969 获 FDA 批准临床>>-- 2026-01-27 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.3% on January 29, with Hualan Vaccine leading the drop [1] - The Shanghai Composite Index closed at 4157.98, up 0.16%, while the Shenzhen Component Index closed at 14300.08, down 0.3% [1] Individual Stock Performance - Weigao Bio (002880) saw a closing price of 30.07, with an increase of 4.59% and a trading volume of 88,100 shares, totaling a transaction value of 266 million yuan [1] - Changchun High-tech (000661) closed at 98.30, up 0.92%, with a trading volume of 64,700 shares and a transaction value of 629 million yuan [1] - Other notable performers include Boya Bio (300294) and Zhifei Biological (300122), both with a closing price increase of 0.92% and 0.73% respectively [1] Declining Stocks - Hualan Bio (301207) reported a significant decline of 9.05%, closing at 22.62, with a trading volume of 300,600 shares and a transaction value of 689 million yuan [2] - Junshi Biosciences (688180) fell by 6.02%, closing at 36.82, with a trading volume of 266,100 shares and a transaction value of 1 billion yuan [2] - Other stocks such as Jinkang (688670) and Bohui Innovation (300318) also experienced declines of 5.81% and 4.95% respectively [2] Capital Flow Analysis - The biopharmaceutical sector saw a net outflow of 866 million yuan from institutional investors, while retail investors contributed a net inflow of 682 million yuan [2] - Notable net inflows from retail investors were observed in stocks like Shanghai Laishi (002252) and Weigao Bio (002880) [3] - Conversely, stocks such as Zhixiang Quantai (688443) and Weigao Bio (002880) experienced significant net outflows from institutional and speculative investors [3]

2023年5月30日，华兰疫苗发布2022年年度权益分派实施公告。公司2022年年度权益分派方案为： 以公司现有总股本400,010,000股为基数，向全体股东每10股派3.00元人民币现金，同时，以资本公积金 向全体股东每10股转增5股。本次权益分派股权登记日为2023年6月6日，除权除息日为2023年6月7日。 (责任编辑：关婧) 上市首日，华兰疫苗盘中创下上市以来最高点79.78元。 华兰疫苗首次公开发行股票募集资金总额为22.76亿元，扣除含税发行费用3156.57万元，实际募集 资金净额为22.44亿元。华兰疫苗此次募集资金比原计划少2.51亿元，公司2021年11月12日披露招股书注 册稿显示，公司拟募集资金24.95亿元，分别用于流感疫苗开发及产业化和现有产品供应保障能力建设 项目、冻干人用狂犬病疫苗开发及产业化建设项目、多联细菌性疫苗开发及产业化建设项目、新型肺炎 疫苗的开发及产业化项目、新型疫苗研发平台建设项目。 华兰疫苗首次公开发行股票的发行费用总额为3156.57万元，其中，华泰联合证券有限责任公司获 得承销费用、保荐费用合计2200.00万元。 中国经济网北京1月29日讯 华兰疫苗(3 ...

Group 1: Nipah Virus Outbreak in India - The recent Nipah virus outbreak in West Bengal, India, has led to 5 confirmed cases, including healthcare workers [1] - Nipah virus is a zoonotic virus that can be transmitted from infected animals to humans, with symptoms including acute respiratory infection and fatal encephalitis [1] Group 2: Company Responses and Developments - Wanfu Bio has launched various Nipah virus nucleic acid test kits, adaptable to their U-CardDx 200 platform and other PCR systems, to meet screening and detection needs [1] - Shengxiang Bio has developed a Nipah virus nucleic acid test kit based on fluorescence PCR technology, with CE certification and a focus on rapid response to public health events [2] - Capbio emphasizes the importance of their Nipah virus test kit for global quarantine and disease control efforts, highlighting its precise detection capabilities [2] - Zhijiang Bio's Nipah virus PCR test kit offers higher sensitivity and accuracy, aiming to shorten the diagnosis window [2] - Da'an Gene has created a Nipah virus nucleic acid test kit with a sensitivity of 200 copies/mL, reducing the risk of false negatives [2] Group 3: Research on Treatment - Research teams from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica have confirmed that the oral nucleoside drug VV116 shows significant antiviral activity against Nipah virus [3] Group 4: Clarifications from Companies - Hualan Biological has clarified that it does not have any products related to Nipah virus, focusing instead on human vaccine manufacturing for influenza [4] - Companies such as Jindike, Yirui Bio, and Renhe Pharmaceutical have publicly stated they do not have any Nipah virus-related products [4]